---
run_id: halo-evidence-vs-diagnosis-validation-v9-generic-advice-prompted-02
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
model_condition: generic_advice_prompted
run_number: 2
model_name: gemma-4-31b-it-mlx
model_id: gemma-4-31b-it-mlx
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
max_tokens: 1024
seed: 205
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 372fe6128e2e633706cc66d44caf0e7dfaf2bba60181854165887aa7ed453ea9
condition_packet_sha256: 372fe6128e2e633706cc66d44caf0e7dfaf2bba60181854165887aa7ed453ea9
output_file: model-outputs/generic_advice_prompted-02.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 02)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v9-v1`, condition `generic_advice_prompted`, run 2 of 8. Real local-model run: `gemma-4-31b-it-mlx` via lmstudio, seed 205, on the frozen condition packet.

## Output

I recommend that you commit to the **Claim File Review**.

### Reasoning
Your current situation is a classic "false positive" loop. You have strong lagging indicators (bookings, renewals) that are being driven by sales incentives (bundle pricing) and roadmap promises rather than realized product value.

The most dangerous signal in your data is the **adjuster behavior**: high initial adoption followed by a collapse back to manual notes, combined with an inability to explain the "why" in regulated segments. This suggests that DraftPath is currently a "manager’s toy"—useful for oversight and enablement demos, but failing the "utility test" for the actual practitioner.

Here is why the other options are insufficient or premature:
*   **Scaling Broadly:** This is a high-risk gamble. If the product lacks fundamental utility for adjusters, you are scaling a "leaky bucket" that will lead to massive churn once the bundle-price honeymoon ends.
*   **Usage Quality Sprint:** This measures *that* people aren't using the tool, but it doesn't tell you *why*. You already know the return rate is low; more dashboards won't fix a fundamental gap in explainability or trust.
*   **Commercial Cleanroom:** This tests the *sales pitch*, not the *product*. While it would prove that the bundle pricing is driving the bookings, it doesn't provide a path to fixing the product. It tells you that you have a revenue problem, but not how to build a value proposition.
*   **Narrowing to Health-Liability:** This is an overreaction. You have evidence of failure there, but you don't yet know if the failure is due to a lack of "explainability" (a solvable product gap) or a fundamental incompatibility with the segment.

The **Claim File Review** is the only option that attacks the "truth" of the value proposition. By auditing the actual claim files, you move from *proxy metrics* (clicks and bookings) to *outcome metrics* (accepted vs. rewritten plans). This will tell you if the AI is actually "right" but poorly presented, or fundamentally wrong.

### The Tradeoff
By choosing the Claim File Review, you are **displacing the Commercial Cleanroom**.

**What you give up:** You sacrifice the ability to definitively prove to the board exactly how much of your Q3 growth was "artificial" (driven by pricing) versus "organic." You will enter next year with a degree of uncertainty regarding your baseline expansion rate because you are not isolating the pricing variable. You are prioritizing **Product-Market Fit** over **Revenue Attribution**.

### The Strongest Reason Against This Recommendation
The Claim File Review is slow and qualitative. It provides a "snapshot" of a small sample size, which may be dismissed by the executive team or board as anecdotal compared to the "hard" 16% growth in bookings. There is a risk that while you are meticulously reviewing files, the sales team continues to sell a vision of DraftPath that the product cannot deliver, widening the gap between expectation and reality.

### Observable Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discover that the "regional carriers" who are removing DraftPath from their contracts are your highest-value, most sophisticated users.

If the "power users" (those who actually know how to use the tool) are the ones churning, while the "low-sophistication" users (who just like the bundle price) are renewing, it indicates that DraftPath is not just "unexplained," but fundamentally non-viable for professional use. In that case, the problem isn't a product tweak—it's a commercial delusion that needs to be corrected immediately via the Cleanroom.
